Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New antidiabetic therapy and HFpEF: light at the end of tunnel?
Marijana Tadić, Carla Sala, Sahrai Saeed, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 4, pp. 1137-1146
Open Access | Times Cited: 20

Showing 20 citing articles:

The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 24
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
Miyesaier Abudureyimu, Xuanming Luo, Xiang Wang, et al.
Journal of Molecular Cell Biology (2022) Vol. 14, Iss. 5
Open Access | Times Cited: 36
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
Kristina Charaya, Dmitry Shchekochikhin, Д. А. Андреев, et al.
Open Heart (2022) Vol. 9, Iss. 1, pp. e001936-e001936
Open Access | Times Cited: 32
Cardiometabolic biomarker patterns associated with cardiac MRI defined fibrosis and microvascular dysfunction in patients with heart failure with preserved ejection fraction
Connor Siggins, Jonathan A. Pan, A Löffler, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications
Giulia La Vecchia, Isabella Fumarulo, Andrea Caffè, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7628-7628
Open Access | Times Cited: 4
The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
Xiaohui Duan, Xiaomeng Zhang, Bao Sun
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
Martina Belli, Lucy Barone, Alfonso Bellia, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14598-14598
Open Access | Times Cited: 18
Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder
Rahul N. Patel, Akash Sharma, Anand Prasad, et al.
Kidney Medicine (2023) Vol. 5, Iss. 12, pp. 100705-100705
Open Access | Times Cited: 10
From bench to bedside: targeting ferroptosis and mitochondrial damage in the treatment of diabetic cardiomyopathy
Bin Liu, Qing Jin, Yi Sun, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
Anjay Rastogi, James L. Januzzi
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2824-2824
Open Access | Times Cited: 9
Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction
Dane Rucker, Jacob Joseph
Current Heart Failure Reports (2022) Vol. 19, Iss. 6, pp. 445-457
Closed Access | Times Cited: 13
Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF
Ying Zhou, Liyao Fu, Jiaxing Sun, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 11
SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?
Yujie Wu, Si-Bo Wang, Liansheng Wang
American Journal of Cardiovascular Drugs (2022) Vol. 22, Iss. 6, pp. 601-613
Closed Access | Times Cited: 7
The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study
Kristina Charaya, D. Yu. Schekochikhin, Т. В. Никифорова, et al.
Kardiologiia (2023) Vol. 63, Iss. 8, pp. 11-18
Closed Access | Times Cited: 3
WATCH-DM risk score predicts the prognosis of diabetic phenotype patients with heart failure and preserved ejection fraction
Xinxin Zhang, Xin Lv, Ning Wang, et al.
International Journal of Cardiology (2023) Vol. 385, pp. 34-40
Open Access | Times Cited: 2
Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility
Matthew K. Burrage, Andrew Lewis, Jack J. Miller
Cardiovascular Drugs and Therapy (2022) Vol. 37, Iss. 2, pp. 379-399
Open Access | Times Cited: 4
Impact of Sex and Gender Differences on Heart Failure, Especially in Elderly Patients
Giuseppe Cocco, Hans Peter Hofmann, Stefano Pandolfi
OBM Geriatrics (2024) Vol. 08, Iss. 01, pp. 1-23
Open Access
Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
Elena-Daniela Grigorescu, C.M. Lǎcǎtusu, Mariana Floria, et al.
Diagnostics (2023) Vol. 13, Iss. 17, pp. 2817-2817
Open Access | Times Cited: 1
Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI
Kathy C. K. Wong, Huda S. Ismail, Kim A. Connelly, et al.
Acta Diabetologica (2023) Vol. 61, Iss. 1, pp. 91-97
Closed Access | Times Cited: 1
The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?
Sugeevan Savarimuthu, Amer Harky
Expert Opinion on Pharmacotherapy (2021) Vol. 23, Iss. 3, pp. 377-386
Closed Access | Times Cited: 1
Page 1

Scroll to top